Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

The latest interleukin: IL-33 the novel IL-1-family member is a potent mast cell activator.

Castellani ML, Kempuraj D, Salini V, Vecchiet J, Tete S, Ciampoli C, Conti F, Cerulli G, Caraffa A, Antinolfi P, Theoharides TC, De Amicis D, Perrella A, Cuccurullo C, Boscolo P, Shaik Y.

J Biol Regul Homeost Agents. 2009 Jan-Mar;23(1):11-4.

PMID:
19321041
2.

Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32).

Conti P, Youinou P, Theoharides TC.

Autoimmun Rev. 2007 Jan;6(3):131-7. Review.

PMID:
17289547
3.

Disease-associated functions of IL-33: the new kid in the IL-1 family.

Liew FY, Pitman NI, McInnes IB.

Nat Rev Immunol. 2010 Feb;10(2):103-10. doi: 10.1038/nri2692. Review.

PMID:
20081870
4.

[Role of interleukin-9 in asthma and allergic reactions].

Renauld JC.

Bull Mem Acad R Med Belg. 2007;162(5-6):275-82; discussion 283-5. French.

PMID:
18404997
5.

IL-31 a Th2 cytokine involved in immunity and inflammation.

Castellani ML, Felaco P, Galzio RJ, Tripodi D, Toniato E, De Lutiis MA, Fulcheri M, Caraffa A, Antinolfi P, Tetè S, Felaco M, Conti F, Pandolfi F, Theoharides TC, Shaik-Dasthagirisaheb YB.

Int J Immunopathol Pharmacol. 2010 Jul-Sep;23(3):709-13.

PMID:
20943040
6.

A new compound, 1H,8H-pyrano[3,4-c]pyran-1,8-dione, suppresses airway epithelial cell inflammatory responses in a murine model of asthma.

Lee H, Han AR, Kim Y, Choi SH, Ko E, Lee NY, Jeong JH, Kim SH, Bae H.

Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):591-603.

PMID:
19822076
7.

[Immune regulation by IL-27 for therapeutic usage].

Yoshida H.

Nihon Rinsho Meneki Gakkai Kaishi. 2009 Aug;32(4):202-13. Review. Japanese.

8.

A positive feedback loop of IL-21 signaling provoked by homeostatic CD4+CD25- T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice.

Jang E, Cho SH, Park H, Paik DJ, Kim JM, Youn J.

J Immunol. 2009 Apr 15;182(8):4649-56. doi: 10.4049/jimmunol.0804350.

9.

Interleukin-21 as a new therapeutic target for immune-mediated diseases.

Monteleone G, Pallone F, Macdonald TT.

Trends Pharmacol Sci. 2009 Aug;30(8):441-7. doi: 10.1016/j.tips.2009.05.006. Review.

PMID:
19616319
10.

Interleukin-33 biology with potential insights into human diseases.

Palmer G, Gabay C.

Nat Rev Rheumatol. 2011 Jun;7(6):321-9. doi: 10.1038/nrrheum.2011.53. Review.

PMID:
21519352
11.

Impact of IL -9 and IL-33 in mast cells.

Sabatino G, Nicoletti M, Neri G, Saggini A, Rosati M, Conti F, Cianchetti E, Toniato E, Fulcheri M, Caraffa A, Antinolfi P, Frydas S, Pandolfi F, Potalivo G, Galzio R, Conti P, Theoharides TC.

J Biol Regul Homeost Agents. 2012 Oct-Dec;26(4):577-86. Review.

PMID:
23241108
12.

Lipopolysaccharide stimulation of dendritic cells induces interleukin-10 producing allergen-specific T cells in vitro but fails to prevent allergic airway disease.

Ahrens B, Freund T, Rha RD, Dittrich AM, Quarcoo D, Hutloff A, Hamelmann E.

Exp Lung Res. 2009 May;35(4):307-23. doi: 10.1080/01902140802709460.

PMID:
19415548
13.

Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma.

Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T.

Biochem Biophys Res Commun. 2009 Aug 14;386(1):181-5. doi: 10.1016/j.bbrc.2009.06.008.

PMID:
19508862
14.

Cytokine-induced cytokine production by conventional and innate lymphoid cells.

Guo L, Junttila IS, Paul WE.

Trends Immunol. 2012 Dec;33(12):598-606. doi: 10.1016/j.it.2012.07.006. Review.

15.

The biological paths of IL-1 family members IL-18 and IL-33.

Smith DE.

J Leukoc Biol. 2011 Mar;89(3):383-92. doi: 10.1189/jlb.0810470. Review.

PMID:
20952658
16.

Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity.

Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH.

Immunity. 2009 Aug 21;31(2):331-41. doi: 10.1016/j.immuni.2009.08.001.

17.
18.

IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production.

Schneider E, Petit-Bertron AF, Bricard R, Levasseur M, Ramadan A, Girard JP, Herbelin A, Dy M.

J Immunol. 2009 Sep 15;183(6):3591-7. doi: 10.4049/jimmunol.0900328.

19.

Interleukin 21 as a target of intervention in autoimmune disease.

Ettinger R, Kuchen S, Lipsky PE.

Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii83-6. doi: 10.1136/ard.2008.098400. Review.

PMID:
19022821
20.

Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice.

van Es T, van Puijvelde GH, Ramos OH, Segers FM, Joosten LA, van den Berg WB, Michon IM, de Vos P, van Berkel TJ, Kuiper J.

Biochem Biophys Res Commun. 2009 Oct 16;388(2):261-5. doi: 10.1016/j.bbrc.2009.07.152.

PMID:
19660432
Items per page

Supplemental Content

Support Center